Navigation Links
China Medical Technologies Announces the Completion of the Sale of its HIFU Business
Date:12/30/2008

BEIJING, Dec. 31 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has completed the previously announced sale of its High Intensity Focused Ultrasound tumor therapy system business (the "HIFU Business") to Chengxuan International Ltd. ("Chengxuan"), a major shareholder of the Company.

The Company stated the reasons for the sale of the HIFU Business in the press release dated December 18, 2008 which included the conditions in the global financial markets, more stringent regulatory requirements on therapeutic equipment from the State Food and Drug Administration in China (the "SFDA") and the significant capital investments required to obtain U.S. and EU regulatory approvals for the HIFU equipment. The Company wishes to elaborate the above reasons below.

The Company believes that the business conditions and outlook for the HIFU Business has deteriorated significantly due to the recent global financial turmoil. Certain HIFU distributors have recently experienced severe difficulties in obtaining financing in China which have negatively affected their working capital and liquidity. As a result, some of them have delayed their planned delivery schedules of the purchased HIFU equipment from the Company to a much later date and others did not place purchase orders with the Company based on the Company's previous expectations. In addition, certain hospitals that have previously considered purchases of the Company's HIFU equipment have recently informed the relevant HIFU distributors to put their proposals on hold. The Company has also experienced slower collections and recorded higher accounts receivable from the HI
'/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
*Name:
*Comment:
*Email: